Alps Pharmaceutical, a global pharmaceutical company that pioneered the use of phytochemicals in medicine and food, announced the launch of a new Isoquercetin composition, Eubio Isoquercetin. Eubio Isoquercetin derived from Sophora Japonica is expected to deliver more Quercetin to the body via small doses of Isoquercetin.

Eubio Isoquercetin, a water-soluble Isoquercetin composition, protected by three related U.S. patents, demonstrated a significantly higher Quercetin absorbability rate than ordinary Isoquercetin in a human pharmacokinetics study.

"We have succeeded in applying our newly developed flavonoid delivery system to Isoquercetin. Recently, the Harvard-affiliated Beth Israel Deaconess Medical Center (Boston, MA) conducted a phase II clinical trial of Isoquercetin for the prevention of thrombosis mainly due to PDI inhibition in 56 patients with advanced cancer and reported that significant medical effects were observed.

“However, it was also pointed out that the dosage was quite high as an oral drug for prevention probably due to its low water solubility and therefore low absorption rate into the body. This new formulation Eubio®Isoquercetin is expected to be a new generation of Isoquercetin that improves the patient's QOL due to its significantly reduced dosage and excellent water-solubility," Dr. Mitsunori Ono, Executive Corporate/Technology Advisor, Alps Pharmaceutical, said. 

Alps Pharma launches a new water soluble Isoquercetin

Alps Pharmaceutical, a global pharmaceutical company that pioneered the use of phytochemicals in medicine and food, announced the launch of a new Isoquercetin composition, Eubio Isoquercetin. Eubio Isoquercetin derived from Sophora Japonica is expected to deliver more Quercetin to the body via small doses of Isoquercetin.

Eubio Isoquercetin, a water-soluble Isoquercetin composition, protected by three related U.S. patents, demonstrated a significantly higher Quercetin absorbability rate than ordinary Isoquercetin in a human pharmacokinetics study.

"We have succeeded in applying our newly developed flavonoid delivery system to Isoquercetin. Recently, the Harvard-affiliated Beth Israel Deaconess Medical Center (Boston, MA) conducted a phase II clinical trial of Isoquercetin for the prevention of thrombosis mainly due to PDI inhibition in 56 patients with advanced cancer and reported that significant medical effects were observed.

“However, it was also pointed out that the dosage was quite high as an oral drug for prevention probably due to its low water solubility and therefore low absorption rate into the body. This new formulation Eubio®Isoquercetin is expected to be a new generation of Isoquercetin that improves the patient's QOL due to its significantly reduced dosage and excellent water-solubility," Dr. Mitsunori Ono, Executive Corporate/Technology Advisor, Alps Pharmaceutical, said.